Table 3.
Expenditure of therapeutic drugs dispensed between 2018 and 2022
| 2018 | 2019 | 2020 | 2021 | 2022 | Total | P1 | P2 | |
|---|---|---|---|---|---|---|---|---|
| Total therapeutic drugs | 118,297.91 | 138,338.85 | 118,115.51 | 119,952.31 | 131,219.4 | 625,923.98 | 0.807 | – |
| Analgesics | 41,315.1 (34.92) | 49,248.39 (35.60) | 45,255.99 (38.32) | 52,110.56 (43.44) | 47,107.48 (35.90) | 235,037.52 (37.55) | 0.462 | < 0.001 |
| NSAIDs | 10,928.15 (9.24) | 12,455.82 (9.00) | 15,876.91 (13.44) | 12,799.12 (10.67) | 18,969.65 (14.46) | 71,029.65 (11.35) | 0.086 | < 0.001 |
| Ibuprofen | 2200.35 (1.86) | 2679.09 (1.94) | 2720.93 (2.30) | 1446.24 (1.21) | 3051.65 (2.33) | 12,098.26 (1.93) | 0.462 | 0.035 |
| loxoprofen | 2251.35 (1.90) | 2039.09 (1.47) | 2834.1 (2.40) | 1635.78 (1.36) | 1522.87 (1.16) | 10,283.19 (1.64) | 0.221 | < 0.001 |
| Celecoxib | 2221.94 (1.88) | 3452.58 (2.50) | 5206.86 (4.41) | 3096.49 (2.58) | 3160.50 (2.41) | 17,138.37 (2.74) | 0.807 | < 0.001 |
| Caffeine-containing agents | 4202.91 (3.55) | 4927.46 (3.56) | 4685.18 (3.97) | 5944.38 (4.96) | 5793.78 (4.42) | 25,553.71 (4.08) | 0.462 | < 0.001 |
| Opioids | 22,237.89 (18.80) | 26,689.2 (19.29) | 22,059.9 (18.68) | 30,866.94 (25.73) | 20,883.71 (15.92) | 122,737.64 (19.61) | 0.462 | 0.987 |
| Codeine/Ibuprofen | 13,775.59 (11.64) | 15,979.8 (11.55) | 11,367.54 (9.62) | 14,084.68 (11.74) | 12,381.48 (9.44) | 67,589.09 (10.80) | 0.807 | < 0.001 |
| Dihydrocodeine/acetaminophen | 1888.4 (1.60) | 3458.74 (2.50) | 1470.24 (1.24) | 3073.32 (2.56) | 2935.92 (2.24) | 12,826.62 (2.05) | 1.000 | < 0.001 |
| Acetaminophen | 357.25 (0.30) | 530.52 (0.38) | 291.16 (0.25) | 225.28 (0.19) | 401.30 (0.31) | 1805.51 (0.29) | 0.807 | < 0.001 |
| CPMs | 3588.9 (3.03) | 4645.39 (3.36) | 2342.84 (1.98) | 2274.84 (1.90) | 1059.04 (0.81) | 13,911.01 (2.22) | 0.086 | < 0.001 |
| Migraine-specific agents | 76,982.81 (65.08) | 89,090.46 (64.40) | 72,859.52 (61.68) | 67,841.75 (56.56) | 84,111.92 (64.10) | 390,886.46 (62.45) | 0.807 | < 0.001 |
| Triptans | 75,457.21 (63.79) | 89,090.46 (64.40) | 72,859.52 (61.68) | 67,841.75 (56.56) | 84,111.92 (64.10) | 389,360.86 (62.21) | 0.807 | < 0.001 |
| Rizatriptan | 51,573.48 (43.60) | 67,463.94 (48.77) | 57,988.95 (49.10) | 51,724.57 (43.12) | 64,657.86 (49.27) | 293,408.8 (46.88) | 0.807 | < 0.001 |
| zolmitriptan | 22,599.21 (19.10) | 21,626.52 (15.63) | 14,870.57 (12.59) | 16,117.18 (13.44) | 19,454.06 (14.83) | 94,667.54 (15.12) | 0.462 | < 0.001 |
| Ergotamine | 1525.6 (1.29) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1525.6 (0.24) | 0.289 | < 0.001 |
| Antiemetics | 1187.64 (1.00) | 1814.57 (1.31) | 1536.61 (1.30) | 954.12 (0.80) | 1368.71 (1.04) | 6861.65 (1.10) | 0.807 | < 0.001 |
NSAIDs nonsteroidal anti-inflammatory drugs, CPMs Chinese patent medicines. P1, P value for the trend in number of prescriptions, assessed by the Mann-Kendall trend test; P2, P value for the trend in the proportion of prescriptions, assessed by the Cochran-Armitage trend test. The number of total therapeutic drugs for each year is the denominator of the data in that column